HBK Sorce Advisory
GTBP icon

HBK Sorce Advisory’s GT Biopharma GTBP Stock Holding History

HBK Sorce Advisory’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17K Hold
400
– – ﹤0.01% 672
2026
Q1 		$3.75K Hold
400
– – ﹤0.01% 664
2025
Q4 		$5.39K Buy
+400
New +$7.1K ﹤0.01% 628

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $479M AUM 15.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

HBK Sorce Advisory's GTBP Position: Q2 2026 in Review

HBK Sorce Advisory held its GT Biopharma (GTBP) position steady in Q2 2026 at 400 shares worth $3.17K. The position accounts for ﹤0.01% of the portfolio, ranked #672.

HBK Sorce Advisory first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.39K in Q4 2025. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • HBK Sorce Advisory held 400 shares of GT Biopharma worth $3.17K as of Q2 2026.
  • HBK Sorce Advisory left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #672 holding.
  • HBK Sorce Advisory first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • HBK Sorce Advisory's GT Biopharma position peaked at $5.39K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.